why choose us

First received: June 09, 2023

Clinical Trial: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Study Status: Completed

Recruit Status: RECRUITING

Condition: Urothelial Carcinoma

Study Type: INTERVENTIONAL


Official Title: An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced or Metastatic Urot

Brief Summary: This study will enroll participants with urothelial cancer (UC).UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra).This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC.This study will also test what side effects happen when participants take these drugs together.A side effect is anything a drug does to the body besides treating the disease.Participants…

Read more